The U.S. Court of Appeals for the Federal Circuit again addressed enablement for prescription drug claims, overturning a jury verdict that AstraZeneca should pay Wyeth, a Pfizer unit, $107.5 million for infringing two cancer patents. The precedential decision highlights how courts continue to refine the evidentiary thresholds for what constitutes sufficiently enabled claims. For biotech companies involved in patent-heavy oncology development, the ruling is a reminder that claim scope and disclosure adequacy can be decisive—especially when patent disputes involve complex therapeutic structures. The case adds to ongoing litigation dynamics between major drug developers and reinforces how appellate review can change the practical outcomes of patent infringement claims, including potential damages exposure.